Switching to aripiprazole in subjects with Pervasive Developmental Disorders showing tolerability issues with risperidone

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 37, Issue 1, 2012, Pages 128-131

  Ishitobi, Makoto ^a,b   Hiratani, Michio ^b   Kosaka, Hirotaka ^a   Takahashi, Tetsuya ^a   Mizuno, Tomoyuki ^a   Asano, Mizuki ^a   Murata, Tetsuhito ^a   Tomoda, Akemi ^a   Wada, Yuji ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b Hiratani Child Development Clinic   (Japan)

Author keywords

Aripiprazole; Behavioral symptoms; Pervasive Developmental Disorders (PDD); Risperidone; Tolerability issues

Indexed keywords

ARIPIPRAZOLE; RISPERIDONE;

ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERPROLACTINEMIA; INCREASED APPETITE; MALE; OUTCOMES RESEARCH; RETROSPECTIVE STUDY; SCHOOL CHILD; SCORING SYSTEM; SOMNOLENCE;

ADOLESCENT; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; PIPERAZINES; QUINOLONES; RETROSPECTIVE STUDIES; RISPERIDONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862801316     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.12.015     Document Type: Article

References (34)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Press, Washington.
2. Anderson G.M., Scahill L., McCracken J.T., McDougle C.J., Aman M.G., Tierney E., et al. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007, 61:545-550.
3. Barnard L., Young A.H., Pearson J., Geddes J., O'Brien G. A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 2002, 16:93-101.
4. Biederman J., McDonnell M.A., Wozniak J., Spencer T., Aleardi M., Falzone R., et al. Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. CNS Spectr 2005, 10:141-148.
5. Biederman J., Mick E., Spencer T., Doyle R., Joshi G., Hammerness P., et al. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 2007, 12:683-689.
6. Canitano R., Scandurra V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neuropsychiatr Dis Treat 2008, 4:723-730.
7. Casey D.E., Carson W.H., Saha A.R., Liebeskind A., Ali M.W., Jody D., et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003, 166:391-399.
8. Chen C.K., Huang Y.S., Ree S.C., Hsiao C.C. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1495-1499.
9. DiLalla D.L., Rogers S.J. Domains of the Childhood Autism Rating Scale: relevance for diagnosis and treatment. J Autism Dev Disord 1994, 24:115-128.
10. Findling R.L., Kauffman R.E., Sallee F.R., Carson W.H., Nyilas M., Mallikaarjun S., et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Psychopharmacol 2008, 28:441-446.
11. Findling R.L., Robb A., Nyilas M., Forbes R.A., Jin N., Ivanova S., et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008, 165:1432-1441.
12. Hirose T., Uwahodo Y., Yamada S., Miwa T., Kikuchi T., Kitagawa H., et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004, 18:375-383.
13. Ishitobi M., Kosaka H., Shukunami K., Murata T., Wada Y. Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1361-1362.
14. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002, 441:137-140.
15. Lemmon M.E., Gregas M., Jeste S.S. Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population. J Child Neurol 2011, 26:428-432.
16. Leskovec T.J., Rowles B.M., Findling R.L. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 2008, 16:97-112.
17. Levy S.E., Hyman S.L. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev 2005, 11:131-142.
18. Lord C., Rutter M., Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994, 24:659-685.
19. Marcus R.N., Owen R., Kamen L., Manos G., McQuade R.D., Carson W.H., et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009, 48:1110-1119.
20. Marcus R.N., Owen R., Manos G., Mankoski R., Kamen L., McQuade R.D., et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol 2011, 21:229-236.
21. Masi G., Cosenza A., Mucci M., Brovedani P. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003, 64:1039-1047.
22. Masi G., Cosenza A., Millepiedi S., Muratori F., Pari C., Salvadori F. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. CNS Drugs 2009, 23:511-521.
23. McDougle C.J., Scahill L., Aman M.G., McCracken J.T., Tierney E., Davies M., et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005, 162:1142-1148.
24. McPheeters M.L., Warren Z., Sathe N., Bruzek J.L., Krishnaswami S., Jerome R.N., et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 2011, 127:e1312-e1321.
25. Myers S.M. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother 2007, 8:1579-1603.
26. Naber D., Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:1213-1219.
27. Nicolson R., Awad G., Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998, 37:372-376.
28. Owen R., Sikich L., Marcus R.N., Corey-Lisle P., Manos G., McQuade R.D., et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009, 124:1533-1540.
29. Prinseton N.J., Bristol-Myers S., Rockville M.D. Aripiprazole: (Abilify) U.S. Full Prescribing Information 2009, Otsuka America Pharmaceutical, Inc.
30. Rugino T.A., Janvier Y.M. Aripiprazole in children and adolescents: clinical experience. J Child Neurol 2005, 20:603-610.
31. Shea S., Turgay A., Carroll A., Schulz M., Orlik H., Smith I., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114:634-641.
32. Titusville N.J. Risperidone: (Risperdal) U.S. Full Prescribing Information 2009, Janssen, Division of Ortho-McNeil-janssen Pharmaceuticals Inc.
33. West L., Waldrop J., Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009, 23:75-89.
34. Zuddas A., Di Martino A., Muglia P., Cianchetti C. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 2000, 10:79-90.